European Case Law Identifier: | ECLI:EP:BA:2011:T084007.20110914 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 14 September 2011 | ||||||||
Case number: | T 0840/07 | ||||||||
Application number: | 02777137.7 | ||||||||
IPC class: | C07K 14/705 A61K 38/18 A61P 37/06 |
||||||||
Language of proceedings: | EN | ||||||||
Distribution: | C | ||||||||
Download and more information: |
|
||||||||
Title of application: | Peptides capable of modulating immune response | ||||||||
Applicant name: | CellAct Pharma GmbH | ||||||||
Opponent name: | - | ||||||||
Board: | 3.3.04 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Unity of invention (yes) Remittal (yes) Reimbursement of appeal fee (no) |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t070840eu1.html
Date retrieved: 17 May 2021